Soligenix Inc. (SNGX)
NASDAQ: SNGX
· Real-Time Price · USD
1.97
0.00 (0.00%)
At close: May 09, 2025, 3:59 PM
2.00
1.52%
After-hours: May 09, 2025, 04:55 PM EDT
0.00% (1D)
| Bid | 1.88 |
| Market Cap | 6.43M |
| Revenue (ttm) | 119.37K |
| Net Income (ttm) | -8.27M |
| EPS (ttm) | -4.98 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | -0.61 |
| Analyst | n/a |
| Ask | 2.12 |
| Volume | 20,345 |
| Avg. Volume (20D) | 86,250 |
| Open | 1.95 |
| Previous Close | 1.97 |
| Day's Range | 1.95 - 1.99 |
| 52-Week Range | 1.68 - 14.83 |
| Beta | 2.07 |
About SNGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SNGX
Website n/a
3 weeks ago
-9.68%
Soligenix shares are trading lower after the compa...
Unlock content with
Pro Subscription
7 months ago
+28.16%
Soligenix shares are trading higher following a report suggesting that police cordoned off two tracks at a Germany train station due to fears that a traveler was infected by the Marburg virus. The company, in April 2024, announced that the FDA granted it an orphan drug designation for the active ingredient in MarVax.
6 months ago · prismmediawire.com
Soligenix, Inc. to Present at the 2024 ThinkEquity ConferencePrinceton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc.